C-Met Overexpression in Inflammatory Breast Carcinomas: Automated Quantification on Tissue Microarrays

Overview

Journal Br J Cancer

Specialty Oncology

Date 2007 Jan 24

PMID 17242702

Citations 18

Authors

S Garcia

J-P Dales

J Jacquemier

E Charafe-Jauffret

D Birnbaum

L Andrac-Meyer

M-N Lavaut

C Allasia

S Carpentier-Meunier

P Bonnier

C Charpin-Taranger

Affiliations

Soon will be listed here.

Abstract

Inflammatory breast carcinoma (IBC) is a rare but aggressive tumour associated with poor outcome owing to early metastases. Increased expression of c-Met protein correlates with reduced survival and high metastatic risk in human cancers including breast carcinomas and is targetable by specific drugs, that could potentially improve the prognosis. In the present study, we compared c-Met expression in IBC (n=41) and non-IBC (n=480) immunohistochemically (Ventana Benchmark autostainer) in two tissue microarrays (TMA) along with PI3K and E-cadherin. The results were quantified through an automated image analysis device (SAMBA Technologies). We observed that (i) c-Met was significantly overexpressed in IBC as compared with non-IBC (P<0.001), (ii) PI3K was overexpressed (P<0.001) in IBC, suggesting that the overexpressed c-Met is functionally active at least through the PI3K signal transduction pathway; and (iii) E-cadherin was paradoxically also overexpressed in IBC. We concluded that overexpressed c-Met in IBC constitutes a potential target for specific therapy for the management of patients with poor-outcome tumours such as IBC. Automated image analysis of TMA proved to be a valuable tool for high-throughput immunohistochemical quantification of the expression of intratumorous protein markers.

Citing Articles

Self-Stabilized Supramolecular Assemblies Constructed from PEGylated Dendritic Peptide Conjugate for Augmenting Tumor Retention and Therapy.

Zheng X, Pan D, Chen X, Wu L, Chen M, Wang W Adv Sci (Weinh). 2021; 8(22):e2102741.

PMID: 34623034 PMC: 8596125. DOI: 10.1002/advs.202102741.

E-Cadherin expression in human tumors: a tissue microarray study on 10,851 tumors.

Burandt E, Lubbersmeyer F, Gorbokon N, Buscheck F, Luebke A, Menz A Biomark Res. 2021; 9(1):44.

PMID: 34090526 PMC: 8180156. DOI: 10.1186/s40364-021-00299-4.

Prevalence and Clinicopathological Significance of MET Overexpression and Gene Amplification in Patients with Gallbladder Carcinoma.

Kim Y, Bang S, Jee S, Park S, Shin S, Jang K Cancer Res Treat. 2019; 52(2):481-491.

PMID: 31645095 PMC: 7176974. DOI: 10.4143/crt.2019.370.

TGFβ1 regulates HGF-induced cell migration and hepatocyte growth factor receptor MET expression via C-ets-1 and miR-128-3p in basal-like breast cancer.

Breunig C, Erdem N, Bott A, Greiwe J, Reinz E, Bernhardt S Mol Oncol. 2018; 12(9):1447-1463.

PMID: 30004628 PMC: 6120235. DOI: 10.1002/1878-0261.12355.

Developmental therapeutics for inflammatory breast cancer: Biology and translational directions.

Costa R, Santa-Maria C, Rossi G, Carneiro B, Chae Y, Gradishar W Oncotarget. 2016; 8(7):12417-12432.

PMID: 27926493 PMC: 5355355. DOI: 10.18632/oncotarget.13778.

References

Camp R, Chung G, Rimm D . Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002; 8(11):1323-7. DOI: 10.1038/nm791. View

Ginestier C, Charafe-Jauffret E, Bertucci F, Eisinger F, Geneix J, Bechlian D . Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am J Pathol. 2002; 161(4):1223-33. PMC: 3278769. DOI: 10.1016/S0002-9440(10)64399-4. View

Ocal I, Dolled-Filhart M, DAquila T, Camp R, Rimm D . Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer. 2003; 97(8):1841-8. DOI: 10.1002/cncr.11335. View

Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio P . Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003; 3(4):347-61. DOI: 10.1016/s1535-6108(03)00085-0. View

Matsumoto K, Nakamura T . NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci. 2003; 94(4):321-7. PMC: 11160298. DOI: 10.1111/j.1349-7006.2003.tb01440.x. View

Ma P, Maulik G, Christensen J, Salgia R . c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003; 22(4):309-25. DOI: 10.1023/a:1023768811842. View

Christensen J, Schreck R, Burrows J, Kuruganti P, Chan E, Le P . A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 2003; 63(21):7345-55. View

Wang X, Le P, Liang C, Chan J, Kiewlich D, Miller T . Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol Cancer Ther. 2003; 2(11):1085-92. View

Birchmeier C, Birchmeier W, Gherardi E, Vande Woude G . Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003; 4(12):915-25. DOI: 10.1038/nrm1261. View

10.

Dales J, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut M . Long-term prognostic significance of neoangiogenesis in breast carcinomas: comparison of Tie-2/Tek, CD105, and CD31 immunocytochemical expression. Hum Pathol. 2004; 35(2):176-83. DOI: 10.1016/j.humpath.2003.10.008. View

11.

Charafe-Jauffret E, Tarpin C, Bardou V, Bertucci F, Ginestier C, Braud A . Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'. J Pathol. 2004; 202(3):265-73. DOI: 10.1002/path.1515. View

12.

Charpin C, Dales J, Garcia S, Carpentier S, Djemli A, Andrac L . Tumor neoangiogenesis by CD31 and CD105 expression evaluation in breast carcinoma tissue microarrays. Clin Cancer Res. 2004; 10(17):5815-9. DOI: 10.1158/1078-0432.CCR-04-0021. View

13.

Jaiyesimi I, Buzdar A, Hortobagyi G . Inflammatory breast cancer: a review. J Clin Oncol. 1992; 10(6):1014-24. DOI: 10.1200/JCO.1992.10.6.1014. View

14.

Charpin C, Vielh P, Duffaud F, Devictor B, Andrac L, Lavaut M . Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators. J Natl Cancer Inst. 1994; 86(20):1539-45. DOI: 10.1093/jnci/86.20.1539. View

15.

Buzdar A, Singletary S, Booser D, Frye D, Wasaff B, Hortobagyi G . Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin N Am. 1995; 4(4):715-34. View

16.

Charpin C, Garcia S, Bouvier C, Devictor B, Andrac L, Choux R . Automated and quantitative immunocytochemical assays of CD44v6 in breast carcinomas. Hum Pathol. 1997; 28(3):289-96. DOI: 10.1016/s0046-8177(97)90126-x. View

17.

Charpin C, Garcia S, Bouvier C, Martini F, Andrac L, Bonnier P . CD31/PECAM automated and quantitative immunocytochemical assays in breast carcinomas: correlation with patient follow-up. Am J Clin Pathol. 1997; 107(5):534-41. DOI: 10.1093/ajcp/107.5.534. View

18.

Beviglia L, Matsumoto K, Lin C, Ziober B, Kramer R . Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression. Int J Cancer. 1997; 74(3):301-9. DOI: 10.1002/(sici)1097-0215(19970620)74:3<301::aid-ijc12>3.0.co;2-e. View

19.

Charpin C, Garcia S, Bonnier P, Martini F, Andrac L, Choux R . Reduced E-cadherin immunohistochemical expression in node-negative breast carcinomas correlates with 10-year survival. Am J Clin Pathol. 1998; 109(4):431-8. DOI: 10.1093/ajcp/109.4.431. View

20.

Ghoussoub R, Dillon D, DAquila T, Rimm E, Fearon E, Rimm D . Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer. 1998; 82(8):1513-20. DOI: 10.1002/(sici)1097-0142(19980415)82:8<1513::aid-cncr13>3.0.co;2-7. View